Dr. Reddy's: Leading the Way

Published Online: Thursday, August 30, 2012
Follow Pharmacy_Times:


Dr. Reddy’s is a vertically integrated global pharmaceutical company and is among the leaders in the supply of generic active pharmaceutical ingredients (APIs) worldwide. It is the first non-Japanese Asian company listed on the NYSE (RDY). It currently has sales revenues of $2 billion. There are 8 API facilities globally, which are FDA-inspected, and 4 FDA-approved finished dosage facilities servicing the United States.

Through its 3 businesses—Pharmaceutical Services and Active Ingredients, Global Generics, and Proprietary Products—it offers a portfolio of products and services, including APIs, Custom Pharmaceutical Services (CPS), generics, differentiated formulations, and New Chemical Entities (NCEs). Dr. Reddy’s has 13 facilities, including API and finished dosage manufacturing.

At a glance:
  • 50 prescription products are marketed under the Dr. Reddy’s label in 250+ dosing presentations
  • 10 OTC products are marketed in 200+ store-brand packaging presentations (private label)
  • Robust pipeline: 76 ANDAs are pending, of which 40 are Para IV certifications, with 15 tentative approvals and 10 FTFs
  • 26 Rx products are ranked top 3 in market sharea
  • Dr. Reddy’s ranks #10 in total generic prescription volume over the last yearb
  • 14,500+ associates worldwide
With our continuing investments in product development, aggressive acquisitions, and advances in research, processes, and technologies, we’re meeting the demands of a changing market. We have the capabilities to help overcome market entry barriers, such as formulation, manufacturing, API, delivery method, and intellectual property. We are also uniquely positioned to support Rx-to-OTC switches.

Discover for yourself how our diverse line of generics, OTCs, and other affordable medicines can make the difference. Make Dr. Reddy’s your low-cost provider of quality pharmaceutical products.

aIMS Volumes, February 2012
bIMS data dispensed generic TRx MAT, March 2012


For more information, visit www.drreddys.com.

Related Articles
US Marshals have seized $1.5 million worth of unapproved prescription drugs from Stratus Pharmaceuticals at the request of the FDA and the US attorney for the Southern District of Florida.
The FDA has granted orphan drug designation to Prolong Pharmaceuticals’ sickle cell disease treatment.
Mylan Inc. today confirmed that it and its subsidiary Mylan Pharmaceuticals have been sued by Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., and Onyx Pharmaceuticals Inc., in connection with the filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Sorafenib Tablets, 200 mg. This product is the generic version of NEXAVAR®, which is indicated for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
A California drug manufacturer must recall and destroy all of its dietary supplements after a federal court determined that it failed to follow FDA manufacturing practice regulations.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$